Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.
about
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations.Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics.Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancerReview article: acid suppression in non-variceal acute upper gastrointestinal bleeding.Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19Influence of acid secretory status on absorption of omeprazole from enteric coated granules.Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.The use of isotopes in the determination of absolute bioavailability of drugs in humans.Pharmacokinetic drug interaction profiles of proton pump inhibitors.Pharmacologic properties of proton pump inhibitors.Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems.Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.Population pharmacokinetics of omeprazole in a random Iranian population.Helicobacter pylori eradication: role of individual therapy constituents and therapy duration.The effects of dose and diet on the pharmacodynamics of esomeprazole in the horse.Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.The effects of dose and diet on the pharmacodynamics of omeprazole in the horse.Proton pump inhibitory therapy: then and now.Evaluation of the effect of orally administered acid suppressants on intragastric pH in cats.A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children.Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling.Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers.Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.The effects of dose and diet on the pharmacokinetics of omeprazole in the horse.
P2860
Q31044030-D5A9C5E2-A0C1-48D0-A2CD-70ED67473F10Q33222162-7E1712B1-DF45-46A1-85DD-8908CA980BCEQ33224563-1945FBC5-F3CC-4DF3-84C6-90F509DDA2DEQ33572677-49086246-BBED-4073-852D-D946EB11C5F7Q33792368-5ACD2058-6841-4A9D-A69A-8AEDD1588A39Q33912651-1DD04118-D237-4524-B41A-D3D8BA27A4BBQ34347232-24951B4C-D57A-4D42-B65A-E41D407B2F3EQ34358008-838E0A3F-D3F5-4762-BF77-0DA0100305FEQ34378603-448AFEF5-B7A0-4ABE-B553-E71A749734F3Q34550493-ADE42BD1-AE84-4981-908A-ADAF3E0DA4BBQ34570478-72DF5B73-E28E-4DE7-8B87-52F7AD2C2F6AQ35572512-71EA6B36-C76C-4B8A-A80D-FC59C4C9ECB2Q35629813-CE813CB4-9C3A-4073-A0D1-00E0CAF313EEQ35826832-7ECD2FD0-A0D2-4E96-A2EF-EFB6B86D8D97Q35861879-6DF67E45-A670-47F3-970A-18A314697762Q36729180-58AEB5A8-4609-444E-AB63-619B1994DA28Q37128495-88F29978-DF49-4579-AFAA-DFBE388D41FCQ37389725-E1957362-44D1-43DC-9681-E13D2A893CB1Q39002326-55D96C83-3C69-4E86-BE0F-17D9F5717D62Q39341299-71193D6E-41FD-4BB4-B75E-C2B7068B1858Q39460047-25921EDE-183C-4232-8B7D-EDA200570B64Q39466750-972D3BE7-08AC-471A-81BF-394A3BACBC8BQ41060016-46B0359F-5A61-4F00-8E3B-F04B30CF56C4Q43197937-72029D2A-5F56-4CD6-BB86-D00AC7E78748Q43817651-5A75D433-3B15-4F11-B9C0-EDFFA244735DQ44394691-FE987376-2BB9-45DA-B594-905473CB75FCQ46476322-CE811E12-A285-425D-8A40-762331FF45D1Q48463862-7E98D2B2-6171-4238-8625-656D9374D68CQ51368572-45DC2736-8DCB-49AB-8C67-BDE2C01AB14AQ52584725-8D984749-41C3-438E-A56E-305DB149F7A6Q53590651-A1AE9C46-905B-4A43-9304-008F303D16F9Q53874800-C3D3A85C-2963-47FE-9309-0FA976849BB0
P2860
Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.
description
1990 nî lūn-bûn
@nan
1990 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Pharmacokinetics and bioavaila ...... istration in healthy subjects.
@ast
Pharmacokinetics and bioavaila ...... istration in healthy subjects.
@en
Pharmacokinetics and bioavaila ...... istration in healthy subjects.
@nl
type
label
Pharmacokinetics and bioavaila ...... istration in healthy subjects.
@ast
Pharmacokinetics and bioavaila ...... istration in healthy subjects.
@en
Pharmacokinetics and bioavaila ...... istration in healthy subjects.
@nl
prefLabel
Pharmacokinetics and bioavaila ...... istration in healthy subjects.
@ast
Pharmacokinetics and bioavaila ...... istration in healthy subjects.
@en
Pharmacokinetics and bioavaila ...... istration in healthy subjects.
@nl
P2093
P2860
P1476
Pharmacokinetics and bioavaila ...... istration in healthy subjects.
@en
P2093
Andersson T
Cederberg C
Lagerström PO
Lundborg P
Skånberg I
P2860
P304
P356
10.1111/J.1365-2125.1990.TB03679.X
P407
P577
1990-05-01T00:00:00Z